about
Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expressionClinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateTadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of actionAge-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progressionNitric Oxide Synthase is Necessary for Normal Urogenital DevelopmentPotential role of endothelin and nitric oxide in physiology and pathophysiology of the lower urinary tract.Nitric oxide in the lower urinary tract: physiological and pathological implications.Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.Endothelins in the urinary tract.The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies.Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculationProstatic disease and sexual dysfunctionNovel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention.K+ channel modulation of slow wave activity in the guinea-pig prostateTargeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?Current models of human prostate contractility.Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology.Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Correlation between risk factors for vascular disease and the American Urological Association Symptom Score.Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition disorders and erectile dysfunction.Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.Emerging treatment options for benign prostatic obstruction.Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.Relaxing effect of acetylcholine on phenylephrine-induced contraction of isolated rabbit prostate strips is mediated by neuronal nitric oxide synthase.Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study.Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation.Stimulators and activators of soluble guanylate cyclase for urogenital disorders.Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication.S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)-Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview.
P2860
Q22254649-1C4B6CA4-3E05-4063-9169-E576E8B4C62DQ26775925-39C8406E-1C92-4A08-A515-3B3B691B23FDQ26783529-7F8BFF51-7294-417B-A9F2-858F7A8F9B56Q27027373-0AB6887F-EF8E-4F58-BAA2-D1677D9F4468Q33699907-A02DF2A1-2CD8-4701-B61B-9AEEDE8E1D11Q33795473-26845FF8-2B63-44B1-96BB-ECDE2F1082F0Q33874486-0AD57BDA-6881-4F41-BBE5-BFC1927878F5Q33953840-C1A0A19F-F22A-473D-8090-7EF969EE4EF2Q33961986-167D9CE0-534A-4A3A-A49B-63AE53057C4AQ34190626-D7980577-3B15-48EF-AFA9-FFB1AE794DABQ34485602-ABF9B674-AEBE-48A4-908E-BC6F63221AB7Q34589643-E4643CCD-0083-4F54-A62C-BE91EF5D99BCQ35070009-CAE7F34E-2AD7-4851-88D9-173065574B29Q35089850-E1A567D2-0C4E-4902-AF2A-EBDE23A7B2DBQ35182377-6BE95AC8-F19D-4D88-ADBC-C2C9BBA6322EQ36053134-7CCF788E-880F-4E04-BA7C-2E86945B0237Q36206614-425B1814-92BF-4E49-9E43-A1111249323BQ36262202-DC33DBEC-6A54-4580-94F4-90663AAEA89BQ36409135-508ECA6A-B90E-452A-889F-A7DF4D544514Q36543120-181BFDD7-B4A4-4E4D-B743-E138BEBAFC03Q36709646-34EEB7C1-B494-4286-8C53-730B57DAD823Q37082856-6E6CB5F8-39CD-4DAC-B2C1-3E730E3B69EFQ37466573-D8E29DA5-5049-4312-84EA-64F94C01B13AQ37863036-752513D3-984F-4676-8F4D-37C0C8DFB2E2Q37896170-D7F74B76-D451-46DF-A3D4-6B5F190A0735Q39195242-E2B6FDC6-0A0E-4699-85C0-9BC09E1994C4Q39344228-80AB0D04-BBE1-41FD-9573-0D266914DC42Q40867167-F1C99B64-7ED7-4C60-9DEE-A02698AA5240Q41961516-DA317B1C-B732-4D9E-BA59-325CE54FECDDQ44922802-9E86C6ED-F0E4-46F6-9F65-CB75C972D566Q47603923-4CE4BE16-3C49-4EA8-83F7-085F4DAEDDC4Q48471767-DE52AB62-E87E-43AF-9C7B-160249AA8859Q52641442-55D2CF14-F937-45D3-B6BF-DEFA2B586103
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Effects of nitric oxide on human and canine prostates.
@en
Effects of nitric oxide on human and canine prostates.
@nl
type
label
Effects of nitric oxide on human and canine prostates.
@en
Effects of nitric oxide on human and canine prostates.
@nl
prefLabel
Effects of nitric oxide on human and canine prostates.
@en
Effects of nitric oxide on human and canine prostates.
@nl
P2093
P1433
P1476
Effects of nitric oxide on human and canine prostates.
@en
P2093
P304
P356
10.1016/S0090-4295(99)80013-2
P407
P577
1995-03-01T00:00:00Z